Pearce IP BioBlast: w/e 14 Feb 2020

March 30, 2020

|

Naomi Pearce & Emily Bristow

On 11 February 2020, Amgen sued Hospira in the District Court of Delaware, alleging Hospira's aBLA for a proposed pegfilgrastim biosimilar infringes Amgen's Neulasta patent for protein purification (no. 8,273,707).

Share on Facebook

Share on Twitter

Please reload

Avastin® | Bevacizumab | Roche/Genentech

September 17, 2020

Aranesp® | Darbepoetin | Amgen

September 17, 2020

Enbrel® | Etanercept | Amgen

September 15, 2020

Rituxan®/MabThera® | Rituximab | Genentech/Biogen

September 3, 2020

Humira® | Adalimumab | AbbVie

September 3, 2020

Stelara® | Ustekinumab | Johnson & Johnson

September 3, 2020

Lucentis® | Ranibizumab | Genentech

September 1, 2020

Keytruda® | Pembrolizumab | Merck

August 31, 2020

Prolia/Xgeva® | Denosumab | Amgen

August 27, 2020

Remicade® | Infliximab | Johnson & Johnson

August 20, 2020

Biosimilars Deals 2020

August 19, 2020

Neulasta® | Pegfilgrastim | Amgen

August 18, 2020

Herceptin® | Trastuzumab | Roche/Genentech

August 13, 2020

Simponi® | Golimumab | Janssen

August 11, 2020

Erbitux® | Cetuximab | BMS/Merck

August 10, 2020

Xolair®| Omalizumab | Genentech / Novartis

July 13, 2020

Eylea® | Aflibercept | Regeneron

June 30, 2020

Neupogen® | Filgrastim (GCSF) | Amgen

June 30, 2020

Soliris®| Eculizumab | Alexion

May 29, 2020

Actemra®/RoActemra® | Tocilizumab | Roche

April 30, 2020

Biosimilars Deals 2018/2019

December 3, 2019

Perjeta® | Pertuzumab | Roche

February 18, 2019

Please reload

Pearce IP BioBlast: w/e 14 Feb 2020

Biosimilars Bulletin

Search by tags